ArticleCureus2025
The Efficacy of Episil® for Radiation-induced Oral Mucositis in Rats.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRadiation therapy is an indispensable treatment for head and neck cancer; however, the development of radiation-induced oral mucositis causes erythema and ulcers in the patient's oral cavity, resulting in severe pain. The purpose of this study was to investigate the efficacy of Episil® in the treatment of radiation-induced oral mucositis. STUDY
designSeventy-six F344 rats were randomly divided into an Episil® group (n=38) and a control group (n=38). After irradiation, the rats were evaluated based on body weight measurements, the oral mucositis index (OMI), tissue myeloperoxidase (MPO) activity, and intraoral bacteria counts.
resultsThe mean ratio of body weight change in the Episil®group was significantly lower than that in the control group. The maximum mean OMI and maximum mean MPO activity did not differ to a statistically significant extent between the Episil® and control groups. The mean bacterial count in the Episil® group was significantly lower than that in the control group on days 8-12.
conclusionsIt is hypothesised that Episil® prevents bacterial infections and body weight loss, potentially suppressing the aggravation of oral mucositis. It is necessary to investigate the bacterial count, the bacterial environments, oral management and the severity of oral mucositis in clinical trials in future to verify the bacterial prevention effect of Episil®.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.